+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
P

Actively Recruiting

Researchers are evaluating the effects and safety of efgartigimod given intravenously in adults with primary immune thrombocytopenia ITP, a condition where the immune system attacks platelets. This phase 3 clinical trial aims to determine how well efgartigimod controls platelet counts compared to a placebo during a 24-week double-blinded treatment period. The study is sponsored by argenx and includes follow-up periods to monitor ongoing effects and safety. Participants will be randomly assigned in a 21 ratio to receive either efgartigimod IV or placebo IV during the double-blinded treatment period. After this, all participants will receive efgartigimod IV during a first 52-week open-label treatment phase, followed by an optional second 52-week open-label phase. After completing these treatment periods, participants will have an approximately 8-week follow-up while off the study drug, with total study participation lasting up to 138 weeks. During the study, participants will have regular blood tests to measure platelet counts and assess disease control. Researchers will track the number of weeks participants maintain platelet counts above specified levels and monitor any bleeding events or adverse effects. Safety is closely observed throughout the trial, including antibody responses to the drug. Participants will have scheduled visits and assessments throughout treatment and follow-up to gather comprehensive data on efgartigimods impact.

Age: 18Years +All GendersPhase 3
94 locations
F

Actively Recruiting

Researchers are conducting an ongoing international observational program called the Fabry Registry to track routine clinical outcomes in patients diagnosed with Fabry disease. This registry includes all patients regardless of their treatment status and aims to improve understanding of the diseases variability, progression, and natural history, including in female patients. It also supports development of monitoring recommendations, characterization of the Fabry population, and evaluation of the long-term safety and effectiveness of Fabrazyme4. The study features a Fabry Pregnancy Sub-registry, which observes pregnancy outcomes in women enrolled in the main registry. This sub-registry collects data on medical and obstetric history, pregnancy, birth outcomes, and infant growth up to 36 months postpartum. Neither the main registry nor the pregnancy sub-registry involve experimental interventions, and patients receive standard care as determined by their treating physicians. Participants undergo clinical assessments and receive their usual care during the registry. Data collected includes safety and effectiveness of treatments like Fabrazyme4 over long periods, as well as pregnancy complications and infant growth measurements. The study is designed to last until 2034, with ongoing monitoring and data collection to support patient care and research without altering treatment plans.

All AgesAll Genders
284 locations
C

Actively Recruiting

This research aims to develop a system for continuously evaluating healthcare quality in semi-intensive care units. By collecting patient data and hospital structure information, the study will identify indicators of unsuccessful care tailored to different patient types. These indicators will help assess the overall quality of care in each semi-intensive care unit over time. The study will last for five years, from 2021 to 2025, during which data from patients admitted to semi-intensive care units will be gathered. Annually, a detailed report will be produced to analyze and compare the results from each unit, helping to track improvements or identify areas needing attention. Participants include all patients hospitalized in participating semi-intensive care units, with an expected total of at least 39,000 patients over the study period. Researchers will monitor outcomes for various patient risk groups to assess healthcare quality. The study involves ongoing data collection and yearly evaluations to support continuous quality improvement in these care units.

All AgesAll Genders
18 locations
E

Actively Recruiting

Researchers are studying mild traumatic brain injury TBI, a common reason for emergency department visits. The study focuses on how brain computed tomography CT scans are used to detect brain injuries in patients with mild TBI. It aims to analyze the variability of CT scan use across Italian emergency departments, evaluate existing scoring systems that guide CT use, and develop a new model to better predict patient outcomes after mild head trauma. The study observes adult patients with mild TBI who present to emergency departments. Researchers will collect data on CT scan use and assess the accuracy of current clinical decision tools like the Canadian CT Head Rule and NICE guidelines. They will then work to create an improved scoring system to help doctors decide when CT scans are necessary, aiming to reduce unnecessary radiation exposure and healthcare costs. Participants will be monitored from September 2025 through August 2027 with data collected on CT scan usage and patient outcomes. The study will validate existing scores between September 2026 and August 2027 and develop a new predictive score by August 2027. Researchers will review patient data, including Glasgow Coma Scale scores, to measure how well the new tool predicts clinically relevant events. The total study duration spans from January 2026 to August 2027.

Age: 18Years +All Genders
59 locations
S

Actively Recruiting

This research investigates patients with newly diagnosed oligometastatic prostate cancer OMPCa who meet the CHAARTED criteria for low metastatic volume disease. The study aims to collect data in a registry from major urological centers in the Triveneto region to evaluate how local treatments, such as surgery or radiotherapy of the primary tumor, combined with systemic hormonal therapies, affect cancer outcomes and quality of life. Patients with high volume metastatic disease, defined by specific bone and visceral metastases criteria, are excluded from this study. The study is observational and involves patients receiving local treatment for their primary prostate cancer along with systemic hormonal therapy, which may be androgen deprivation therapy ADT alone or combined with other agents like Docetaxel or androgen receptor signal inhibitors ARTA. Participants will be followed to observe outcomes without randomization or comparison groups since this is a single-arm study. Participants will be monitored for overall survival, cancer-specific survival, progression to castration-resistant prostate cancer, radiological progression, quality of life, as well as treatment complications for up to three years. Data collection includes clinical assessments and quality of life evaluations from the start of treatment through follow-up. The study helps track how these treatments impact patients over time in routine clinical practice.

Age: 18Years +MALE
12 locations
Q

Actively Recruiting

Researchers are studying the quality of life QoL changes in elderly patients with low-grade non-Hodgkin lymphoma during their clinical management. This observational, prospective study aims to identify key factors at diagnosis and during treatment that affect QoL. The study includes patients aged 70 years and older with confirmed indolent B cell non-Hodgkin lymphoma who are starting treatment for the first time. Participants may receive any type of lymphoma treatment as decided by their doctors, including immunotherapy, immunochemotherapy at full or reduced doses, or radiotherapy. All patients undergo a Comprehensive Geriatric Assessment before starting treatment. The study observes QoL at three points before treatment begins, at the end of treatment which can last from 1 to 6 months, and one year after treatment starts. Throughout the study, patients follow their usual clinical care routines, with assessments and response evaluations done as part of standard practice. Quality of life is measured using established questionnaires EORTC-QLQ-C30 and FACT-Lym-LymS. Researchers also track overall survival, progression-free survival, event-free survival, response rates, and safety data over up to 30 months. Participants are involved in routine clinical visits and complete QoL questionnaires at specified times during the study.

Age: 70Years +All Genders
21 locations
R

Actively Recruiting

This observational study focuses on adult patients with Paroxysmal Nocturnal Hemoglobinuria PNH in Italy who are treated with iptacopan. The research aims to evaluate the long-term hematological response to iptacopan, including changes in hemoglobin levels and avoidance of red blood cell transfusions over 12 months. The study uses real-world clinical data to better understand treatment outcomes in routine practice. Participants include those new to iptacopan treatment as well as patients transitioning from a Managed Access Program. The study collects data retrospectively, prospectively, and retro-prospectively, following patients from the start of iptacopan treatment for up to 24 months or until treatment discontinuation or other endpoints occur. No additional visits or procedures beyond routine care are required, though questionnaires may be collected during scheduled clinical visits. During the study, researchers will monitor hemoglobin levels, transfusion needs, adverse events, and patient-reported outcomes using validated questionnaires. Data on hospitalizations, infections, vascular events, medication adherence, and quality of life will also be collected. This approach allows assessment of iptacopans effects and safety in a real-world setting without altering standard medical care.

Age: 18Years +All Genders
12 locations